← FDA DRUG APPROVALS

FDA NDA · NDA213422

WYNZORA

calcipotriene and betamethasone dipropionate

Sponsor: MC2

APPLICATION
NDA213422
TYPE
NDA
ORIGINAL APPROVAL
2020-07-20
LATEST ACTION
2020-07-20
ROUTE
TOPICAL
DOSAGE FORM
CREAM
MARKETING STATUS
Prescription

Products

WYNZORA · ReferencePrescription
BETAMETHASONE DIPROPIONATE 0.064%, CALCIPOTRIENE 0.005% · CREAM · TOPICAL

Approval history

2020-07-20Type 5 - New Formulation or New Manufacturer · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →